Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Utreloxastat - PTC Therapeutics

Next Previous
Drug Profile

Utreloxastat - PTC Therapeutics

Alternative Names: EPI 857; PTC-857

Latest Information Update: 11 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioElectron Technology
  • Developer PTC Therapeutics
  • Class Antiparkinsonians; Cyclohexanes; Ketones; Neuroprotectants; Small molecules
  • Mechanism of Action 15-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis
  • Discontinued Parkinson's disease

Most Recent Events

  • 26 Mar 2025 PTC therapeutics terminated phase-II clinical trials in Amyotrophic lateral sclerosis in US, France, Argentina, Australia, Belgium, Czech Republic, Germany, Italy, Netherlands, Poland, Spain, Sweden and Norway due to company decision (PO) (NCT05349721)
  • 13 Jun 2024 Discontinued - Phase-I for Parkinson's disease (In volunteers) in USA (unspecified route) prior to July 2024 (PTC therapeutics pipeline, June 2024)
  • 29 Feb 2024 PTC therapeutics plans a phase II/III trial for Amyotrophic lateral sclerosis (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top